Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide

Tzong Shin Tzai, Johnny Shinn Nan Lin, Nan Haw Chow

研究成果: Article

14 引文 (Scopus)

摘要

As a tumor progressively grows, the tumor-bearing host usually is under a tumor-mediated immune suppression status. Although surgical resection of the tumor may immediately eliminate most tumor-induced detrimental influences, perioperatively the antitumor immunity of the host remains temporarily suppressed. The major purpose of this study is to investigate the modulation effect of low-dose cyclophosphamide (CY) on the antitumor immunity of tumor-bearing mice (TBM). Using the C3H/He-MBT-2 murine bladder tumor model, we demonstrate that low-dose CY (100 mg/kg) intraperitoneal injection 2 days before tumor resection can significantly enhance the specific antitumor immunity of the TBM. It consequently suppresses the outgrowth of perioperative rechallenged tumor cells and improves the survival of the animals. Phenotypic analysis of cellular subset of spleen by flow cytometry revealed that low-dose CY, when given to both naive and tumor-bearing mice, causes significant reduction of both absolute number and percentage of cells with CD4 CD8 subset in the spleens of TBM. As a result of a parallel increase in the percentage of both CD4+CD8 and CD4-CD8+ subsets, the CD4+/CD8+ ratio remains unchanged. However, after short-term in vitro culture with IL-2 the percentage of the CD4 CD8 subset and CD4+/CD8+ ratio markedly decreased because of the relatively predominant proliferation of the CD4+/CD8+ subset. Evidence from in vitro cytotoxicity assays on panel tumor cells and phenotypic analysis revealed that this enhancement of host antitumor immunity, following low-dose CY pretreatment, may be due to augmenting the activity of NK, LAK, and CD11b+ myeloid/macrophages in addition to cytotoxic T lymphocytes.

原文English
頁(從 - 到)139-144
頁數6
期刊Journal of Surgical Research
65
發行號2
DOIs
出版狀態Published - 1996 十月

指紋

Cyclophosphamide
Immunity
Neoplasms
CD4-CD8 Ratio
Spleen
Cytotoxic T-Lymphocytes
Intraperitoneal Injections
Urinary Bladder Neoplasms
Interleukin-2
Cell Survival
Flow Cytometry
Cell Count
Macrophages

All Science Journal Classification (ASJC) codes

  • Surgery

引用此文

Tzai, Tzong Shin ; Lin, Johnny Shinn Nan ; Chow, Nan Haw. / Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide. 於: Journal of Surgical Research. 1996 ; 卷 65, 編號 2. 頁 139-144.
@article{d38af66537744e2199d7eb5b8e49538f,
title = "Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide",
abstract = "As a tumor progressively grows, the tumor-bearing host usually is under a tumor-mediated immune suppression status. Although surgical resection of the tumor may immediately eliminate most tumor-induced detrimental influences, perioperatively the antitumor immunity of the host remains temporarily suppressed. The major purpose of this study is to investigate the modulation effect of low-dose cyclophosphamide (CY) on the antitumor immunity of tumor-bearing mice (TBM). Using the C3H/He-MBT-2 murine bladder tumor model, we demonstrate that low-dose CY (100 mg/kg) intraperitoneal injection 2 days before tumor resection can significantly enhance the specific antitumor immunity of the TBM. It consequently suppresses the outgrowth of perioperative rechallenged tumor cells and improves the survival of the animals. Phenotypic analysis of cellular subset of spleen by flow cytometry revealed that low-dose CY, when given to both naive and tumor-bearing mice, causes significant reduction of both absolute number and percentage of cells with CD4 CD8 subset in the spleens of TBM. As a result of a parallel increase in the percentage of both CD4+CD8 and CD4-CD8+ subsets, the CD4+/CD8+ ratio remains unchanged. However, after short-term in vitro culture with IL-2 the percentage of the CD4 CD8 subset and CD4+/CD8+ ratio markedly decreased because of the relatively predominant proliferation of the CD4+/CD8+ subset. Evidence from in vitro cytotoxicity assays on panel tumor cells and phenotypic analysis revealed that this enhancement of host antitumor immunity, following low-dose CY pretreatment, may be due to augmenting the activity of NK, LAK, and CD11b+ myeloid/macrophages in addition to cytotoxic T lymphocytes.",
author = "Tzai, {Tzong Shin} and Lin, {Johnny Shinn Nan} and Chow, {Nan Haw}",
year = "1996",
month = "10",
doi = "10.1006/jsre.1996.0356",
language = "English",
volume = "65",
pages = "139--144",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide. / Tzai, Tzong Shin; Lin, Johnny Shinn Nan; Chow, Nan Haw.

於: Journal of Surgical Research, 卷 65, 編號 2, 10.1996, p. 139-144.

研究成果: Article

TY - JOUR

T1 - Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide

AU - Tzai, Tzong Shin

AU - Lin, Johnny Shinn Nan

AU - Chow, Nan Haw

PY - 1996/10

Y1 - 1996/10

N2 - As a tumor progressively grows, the tumor-bearing host usually is under a tumor-mediated immune suppression status. Although surgical resection of the tumor may immediately eliminate most tumor-induced detrimental influences, perioperatively the antitumor immunity of the host remains temporarily suppressed. The major purpose of this study is to investigate the modulation effect of low-dose cyclophosphamide (CY) on the antitumor immunity of tumor-bearing mice (TBM). Using the C3H/He-MBT-2 murine bladder tumor model, we demonstrate that low-dose CY (100 mg/kg) intraperitoneal injection 2 days before tumor resection can significantly enhance the specific antitumor immunity of the TBM. It consequently suppresses the outgrowth of perioperative rechallenged tumor cells and improves the survival of the animals. Phenotypic analysis of cellular subset of spleen by flow cytometry revealed that low-dose CY, when given to both naive and tumor-bearing mice, causes significant reduction of both absolute number and percentage of cells with CD4 CD8 subset in the spleens of TBM. As a result of a parallel increase in the percentage of both CD4+CD8 and CD4-CD8+ subsets, the CD4+/CD8+ ratio remains unchanged. However, after short-term in vitro culture with IL-2 the percentage of the CD4 CD8 subset and CD4+/CD8+ ratio markedly decreased because of the relatively predominant proliferation of the CD4+/CD8+ subset. Evidence from in vitro cytotoxicity assays on panel tumor cells and phenotypic analysis revealed that this enhancement of host antitumor immunity, following low-dose CY pretreatment, may be due to augmenting the activity of NK, LAK, and CD11b+ myeloid/macrophages in addition to cytotoxic T lymphocytes.

AB - As a tumor progressively grows, the tumor-bearing host usually is under a tumor-mediated immune suppression status. Although surgical resection of the tumor may immediately eliminate most tumor-induced detrimental influences, perioperatively the antitumor immunity of the host remains temporarily suppressed. The major purpose of this study is to investigate the modulation effect of low-dose cyclophosphamide (CY) on the antitumor immunity of tumor-bearing mice (TBM). Using the C3H/He-MBT-2 murine bladder tumor model, we demonstrate that low-dose CY (100 mg/kg) intraperitoneal injection 2 days before tumor resection can significantly enhance the specific antitumor immunity of the TBM. It consequently suppresses the outgrowth of perioperative rechallenged tumor cells and improves the survival of the animals. Phenotypic analysis of cellular subset of spleen by flow cytometry revealed that low-dose CY, when given to both naive and tumor-bearing mice, causes significant reduction of both absolute number and percentage of cells with CD4 CD8 subset in the spleens of TBM. As a result of a parallel increase in the percentage of both CD4+CD8 and CD4-CD8+ subsets, the CD4+/CD8+ ratio remains unchanged. However, after short-term in vitro culture with IL-2 the percentage of the CD4 CD8 subset and CD4+/CD8+ ratio markedly decreased because of the relatively predominant proliferation of the CD4+/CD8+ subset. Evidence from in vitro cytotoxicity assays on panel tumor cells and phenotypic analysis revealed that this enhancement of host antitumor immunity, following low-dose CY pretreatment, may be due to augmenting the activity of NK, LAK, and CD11b+ myeloid/macrophages in addition to cytotoxic T lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=0030273358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030273358&partnerID=8YFLogxK

U2 - 10.1006/jsre.1996.0356

DO - 10.1006/jsre.1996.0356

M3 - Article

C2 - 8903460

AN - SCOPUS:0030273358

VL - 65

SP - 139

EP - 144

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -